Aurinia Pharmaceuticals (AUPH) Receivables - Other (2019 - 2020)
Aurinia Pharmaceuticals' (AUPH) quarterly Receivables - Other came in at $51000.0 in Q4 2020, down 75.12% YoY from $205000.0 in Q1 2020, and down 75.12% on a QoQ basis from $205000.0 in Q4 2019.
Aurinia Pharmaceuticals (AUPH) Receivables - Other (2019 - 2020) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 2 years of Receivables - Other data on file, last reported at $51000.0 in Q4 2020.
- Quarterly Receivables - Other fell 75.12% year-over-year to $51000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $51000.0 (down 75.12% YoY) and the FY2020 annual result came in at $51000.0, down 75.12% from the prior year.
- Receivables - Other eased to $51000.0 in Q4 2020, from $205000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $205000.0 in Q4 2019 to a low of $51000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 51,000.00 |
| Dec 31, 2020 | 51,000.00 |
| Dec 31, 2019 | 205,000.00 |
| Dec 31, 2019 | 205,000.00 |